CARD14-associated papulosquamous eruption (CAPE) in pediatric patients: Three additional cases and review of the literature.

Autor: Frare CP; Department of Dermatology, Hospital Alemán, Buenos Aires, Argentina., Blumstein AJ; Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Paller AS; Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Pieretti L; Dr Úraga Private Center for Skin Diseases, Guayaquil, Ecuador., Choate KA; Department of Genetics, Yale University School of Medicine, New Haven, CT, USA., Bowcock AM; Dermatology, Oncological Sciences and Genetics & Genomics, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Larralde M; Department of Dermatology, Hospital Alemán, Buenos Aires, Argentina.; Department of Pediatric Dermatology, Ramos Mejía Hospital, Buenos Aires, Argentina.
Jazyk: angličtina
Zdroj: Pediatric dermatology [Pediatr Dermatol] 2021 Sep; Vol. 38 (5), pp. 1237-1242. Date of Electronic Publication: 2021 Aug 26.
DOI: 10.1111/pde.14779
Abstrakt: CARD14-associated papulosquamous eruption (CAPE) is a proposed term that encompasses features ranging from psoriasis to pityriasis rubra pilaris (PRP) in association with CARD14 mutations. The early onset of the disease, prominent facial involvement, family history of an autosomal dominant trait, and poor response to conventional treatment are characteristics of CAPE that distinguish it from classical psoriasis and PRP. We describe the clinical features, family history, and response to therapy in three unrelated children with CAPE and compare these characteristics with those of previously described pediatric patients. Testing for CARD14 mutations in children with early onset of features of psoriasis or pityriasis rubra pilaris and resistance to conventional therapy should be considered.
(© 2021 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: